Pfizer works to get 'wait-and-see' doctors on board the Ibrance train

Evidence in favor of the relatively new CDK 4/6 class of breast cancer drugs, which stars Pfizer’s Ibrance, continues to pile up—but it hasn’t yet been enough to convince some doctors to give the meds a try.